Pentagon contract could send this $2 AI stock soaring

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Javier San Martin net worth and biography

Javier San Martin Biography and Net Worth

Insider of Arrowhead Pharmaceuticals

Dr. San Martin previously served as Senior Vice President and Head of Global Clinical Development at Ultragenyx since 2013, where he led the development of burosumab, a novel drug for the treatment of X-Linked Hypophosphatemia approved across major regions including the United States, the European Union, and Canada. Before his tenure at Ultragenyx, he served as Senior Vice President of Clinic Development at Alder Biopharmaceuticals, where he was responsible for managing the medical, regulatory, and clinical operations group focused on early clinical programs. From 2006 to 2011, Dr. San Martin was a Global Development Leader at Amgen, Inc., where he was responsible for two major development programs. He directed the romosozumab clinical program through the end of phase II, and before that, was responsible for the development and approval of denosumab, the largest branded anti-osteoporosis treatment for postmenopausal osteoporosis and the first monoclonal antibody to address a very prevalent disease treated by primary care physicians. Prior to his time at Amgen, he spent seven years at Eli Lilly and Company, supporting late stage clinical development as well as medical affairs activities, including the successful launch of Evista and Forteo. He received his medical degree from the University of Buenos Aires Medical School and completed his residence in internal medicine at CEMIC University Hospital in Buenos Aires, Argentina, serving as Chief Resident, and, thereafter, as Attending Physician responsible for the internal medicine ward.

What is Javier San Martin's net worth?: The estimated net worth of Javier San Martin is at least $3.07 million as of November 20th, 2023. Dr. San Martin owns 131,800 shares of Arrowhead Pharmaceuticals stock worth more than $3,069,622 as of April 24th. This net worth evaluation does not reflect any other investments that Dr. San Martin may own. Learn More about Javier San Martin's net worth.
How do I contact Javier San Martin?: The corporate mailing address for Dr. San Martin and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Javier San Martin's contact information.
Has Javier San Martin been buying or selling shares of Arrowhead Pharmaceuticals?: Javier San Martin has not been actively trading shares of Arrowhead Pharmaceuticals in the last ninety days. Most recently, Martin Javier San sold 19,700 shares of the business's stock in a transaction on Monday, November 20th. The shares were sold at an average price of $28.80, for a transaction totalling $567,360.00. Following the completion of the sale, the insider now directly owns 131,800 shares of the company's stock, valued at $3,795,840. Learn More on Javier San Martin's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 408,135 shares worth more than $13,514,007.79. The most recent insider tranaction occured on March, 20th when Director Hongbo Lu bought 1,000 shares worth more than $27,500.00. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 3/20/2024.

Javier San Martin Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2023	Sell	19,700	$28.80	$567,360.00	131,800
11/21/2022	Sell	19,500	$29.99	$584,805.00	91,500
11/19/2021	Sell	19,500	$69.31	$1,351,545.00
11/19/2020	Sell	19,500	$69.39	$1,353,105.00	130,500

Javier San Martin Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $23.29

$22.89

$23.76

50 Day Range

MA: $28.40

$22.33

$36.08

2 Week Range

Now: $23.29

$20.67

$42.48

Volume

813,628 shs

Average Volume

1,464,399 shs

Market Capitalization

$2.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Pentagon contract could send this $2 AI stock soaring

From Behind the Markets | Ad

Get all the info here >>>